论文部分内容阅读
目的:观察不同剂量布地奈德混悬液雾化吸入治疗婴幼儿喘息的疗效。方法:将76例诊断为婴幼儿喘息患儿随机分为三组。对照组地塞米松2～3 mg、病毒唑0.2 g;低剂量组普米克令舒1 ml(含布地奈德0.5 mg)、博利康尼1～2 ml;高剂量组布地奈德1.0 mg、博利康尼1～2 ml雾化吸入。三组所用雾化器、用法、疗程及综合治疗方法均相同。观察比较三组疗效和不良反应。结果:观察组气促缓解、哮鸣音消失、咳嗽消失、平均住院日明显优于对照组,差异有统计学意义(P<0.01);高剂量组与低剂量组气促缓解时间差异无统计学意义(P>0.05),其他优于低剂量组,差异有统计学意义(P<0.05)。显效率比较:高剂量组(93.75%)与低剂量组(68.18%)及低剂量组与对照组(36.36%)差异均有统计学意义(χ2=4.433 5、4.463 7,均P<0.05),高剂量组与对照组差异有统计学意义(χ2=20.591,P<0.01)。未发现不良反应。结论:布地奈德混悬液加博利康尼雾化吸入治疗婴幼儿喘息疗效显著且与剂量有关,高剂量组优于低剂量组。可作为临床治疗婴幼儿喘息有效安全方便的药物使用。
Objective: To observe the effect of different doses of budesonide suspension atomization inhalation in infants respite. Methods: 76 cases diagnosed as infantile asthma were randomly divided into three groups. Control group dexamethasone 2 ~ 3 mg, ribavirubin 0.2 g; low dose group Pulmicort 1 ml (containing budesonide 0.5 mg), 1 to 2 ml of boli Kang; high dose group Budesonide 1.0 mg, Boli Kangni 1 ~ 2 ml inhalation atomization. Three sets of nebulizer, usage, treatment and comprehensive treatment are the same. Three groups were observed and compared the efficacy and adverse reactions. Results: In the observation group, there was no significant difference between the high-dose group and the low-dose group in reducing the time of breathlessness, the disappearance of the wheeze, the disappearance of the cough, and the average length of stay in the observation group, which was significantly better than that in the control group (P <0.01) (P> 0.05), while the others were better than the low dose group (P <0.05). Significantly, there was significant difference between the high dose group (93.75%) and the low dose group (68.18%) and the low dose group (36.36%) (χ2 = 4.433 5, 4.4663 7, both P <0.05) , High-dose group and control group, the difference was statistically significant (χ2 = 20.591, P <0.01). No adverse reactions found. CONCLUSION: Budesonide suspension and Gaborneconi nebulized inhalation have significant effect on the respite of infants and young children, and are dose-dependent. The high dose group is better than the low dose group. It can be used as an effective, safe and convenient drug for the clinical treatment of wheezing in infants and children.